Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Study: Elite scientists can hold back science

Brian Resnick
Brian Resnick was Vox’s science and health editor and is the co-creator of Unexplainable, Vox’s podcast about unanswered questions in science.

Max Planck — the Nobel Prize–winning physicist who pioneered quantum theory — once said the following about scientific progress:

A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it.

Shorter: Science is not immune to interpersonal bullshit. Scientists can be stubborn. They can use their gravitas to steamroll new ideas. Which means those new ideas often only prevail when older scientists die.

Recently, researchers at the National Bureau of Economic Research (NBER) released a working paper — titled, “Does Science Advance One Funeral at a Time?” — that puts Planck’s principle to the test.

Sifting through citations in the PubMed database, they found evidence that when a prominent researcher suddenly dies in an academic subfield, a period of new ideas and innovation follow.

The NBER team identified 12,935 “elite” scientists — based on the amount of funding they receive, how many times they’ve published, how many patents they invented, or whether they were members of the National Academies of Sciences or the Institute of Medicine. Searching through obituaries, they found 452 of these elite researchers died before retirement. Because science leaves a dense paper trail of citations, publish dates, and author bylines, it’s (relatively) easy to track changes in publishing patterns after a prominent death.

Here’s the pattern: After the unexpected death of a rock-star scientist, their frequent collaborators — the junior researchers who authored papers with them — suddenly see a drop in publication. At the same time, there is a marked increase in published work by other newcomers to the field:

The NBER researchers also evaluated NIH grants before and after the deaths, and found a similar pattern.

Unlike the collaborators, presumably, these newcomers are less beholden to the dead luminaries. They were “less likely to cite the deceased star’s work at all,” the report states. And they seemed to be making novel advances in science:

The new articles represent substantial contributions, at least as measured by long-run citation impact. Together, these results paint a picture of scientific fields as scholarly guilds to which elite scientists can regulate access, providing them with outsized opportunities to shape the direction of scientific advance in that space.

All this suggest there’s a “goliath’s shadow” effect. People are either prevented from or afraid of challenging a leading thinker in a field. That or scientific subfields are like grown-up versions of high school cafeteria tables. New people just can’t sit there until the queen bee dies.

What’s interesting is that the deaths seemed to hurt the careers of the luminaries’ junior collaborators, the ones who frequently co-authored papers with them but not in a senior role. “The death of an elite scientist has a negative and seemingly permanent impact on the productivity of their coauthors,” the study reports. They published less, while outsiders flooded the void.

(The authors caution that gatekeeping by elite researchers isn’t always a bad thing. “Gatekeeping activities could have beneficial properties when [a] field is in its inception,” granting scientists more room to take risks.)

All of this is another example of how progress in science is confounded by human behavior. We see this in so many ways. Scientists lie about results. Or they discount insights derived from failures. Science is so obsessed with the rewards of solving complicated problems that it forgets about the simple ones. The field overwhelmingly is biased toward males (experiments have shown “John” gets more accolades than “Jennifer” with the identical résumé).

It’s worth remembering: Science may be a noble discipline based on cold logic and rational observation; but humans are animals fueled by emotion and bias. As the NBER researchers conclude: “[T]he idiosyncratic stances of individual scientists can do much to alter, or at least delay, the course of scientific advance.”


Vox Featured Video

Slowing down climate change isn't about saving the planet. It's about saving us.

See More:

More in Science

Future Perfect
Human bodies aren’t ready to travel to Mars. Space medicine can help.Human bodies aren’t ready to travel to Mars. Space medicine can help.
Future Perfect

Protecting astronauts in space — and maybe even Mars — will help transform health on Earth.

By Shayna Korol
Podcasts
The importance of space toilets, explainedThe importance of space toilets, explained
Podcast
Podcasts

Houston, we have a plumbing problem.

By Peter Balonon-Rosen and Sean Rameswaram
Climate
How climate science is sneakily getting funded under TrumpHow climate science is sneakily getting funded under Trump
Climate

Scientists are keeping their climate work alive by any other name.

By Kate Yoder, Ayurella Horn-Muller and 1 more
Good Medicine
You can’t really “train” your brain. Here’s what you can do instead.You can’t really “train” your brain. Here’s what you can do instead.
Good Medicine

The best ways to protect your cognitive health might surprise you.

By Dylan Scott
Future Perfect
Humanity’s return to the moon is a deeply religious missionHumanity’s return to the moon is a deeply religious mission
Future Perfect

Space barons like Jeff Bezos and Elon Musk don’t seem religious. But their quest to colonize outer space is.

By Sigal Samuel
Health
Why the new GLP-1 pill is such a big dealWhy the new GLP-1 pill is such a big deal
Health

The FDA just approved Foundayo. Here’s what it can and can’t do.

By Dylan Scott